Designed to recognize two or more distinct epitopes in the same or different targets, multispecific antibodies represent a new generation of large molecule therapeutics.
Designed to recognize two or more distinct epitopes in the same or different targets, multispecific antibodies represent a new generation of large molecule therapeutics. Multispecific antibodies particularly bispecific and trispecific antibodies have been gaining traction as a way to confer new therapeutic functionalities, such as the simultaneous engagement of T cells and tumor cell. Till date, four bispecific antibodies have entered the market whereas trispecific antibodies are mainly confined to clinical development, and are expected to enter the market during the forthcoming years.
GTB-3550 developed by GT Biopharma represents one of the leading trispecific killer engager (TriKe) which is present in phase-I/II clinical studies for the treatment of relapsed/refractory acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Apart from this, the company has also developed GTB-4550 and GTB-5550 for the treatment of solid tumors. Apart from this, HPN217 developed by Harpoon Therapeutics has also shown encouraging response in the management of cancer and has been granted orphan drug designation by US FDA in 2021.
The promising response of bispecific antibodies in the market has increased the competition among pharmaceutical companies to actively invest in this sector. The global market has witness an increase in collaboration and partnerships to drive the research and development of bispecific antibody. Biomunex Pharmaceuticals and Institut Curie announced strategic collaboration in which the companies will work on the development of a breakthrough immunotherapy drug candidate for the treatment of hematological malignancies and solid tumors, based on Biomunex’ unique proprietary BiXAb technology. In addition, ABL Bio announced an exclusive collaboration and worldwide license agreement with Sanofi to develop and commercialize ABL301, a pre-clinical stage bispecific antibody targeting alpha-synuclein and IGF1R to treat Parkinson’s disease and other potential indications with enhanced blood-brain barrier (BBB) penetration. The other key players in the market include Amgen, Roche, Janssen, F-Star Therapeutics, Biogen, and others.
Global Trispecific Antibody Market Opportunity And Clinical Trials Insight 2028 Report Analysis and Data Highlights:
- Research Methodology
- Global Market Analysis
- Global Trispecific Antibody Market Opportunity Assessment: > USD 2 Billion
- US To Dominate Trispecific Antibodies Market: >70%
- Market and Drug Sales Insight 2024 Till 2028
- Future Market Assessment By Indication Till 2028
- Ongoing Clinical Trials Assessment by Status, Phase and Region
- Key Market Dynamics
- Competitor Landscape
Download Report:
Global Bispecific Antibody Market Insight 2028 Report Highlights:
- Research Methodology
- Global and Regional Market Analysis
- Global Bispecific Antibody Market Opportunity Assessment: > USD 20 Billion
- Market Sales Insight 2020 Till 2028
- Approved Drug Sales Insight Till Dec 2021(Updated Every Quarter)
- Approved Drug Sales Forecast Till 2028
- Approved Drug In Market: 4 Drugs
- Approved Bispecific Antibody Drug Patent, Price and Sales insight 2020 Till 2028
- Future Market Assessment By Indication Till 2028
- Ongoing Clinical Trials Assessment by Status, Phase and Region
Download Report:
The most promising targets for multispecific antibodies are CD19, CD20, and BCMA in blood malignancies and EGFR and HER2 in solid tumors. However, with the advancement in genomic fingerprinting and better understanding in the cancer biology has led to identification of other potential cancer targets which will further create opportunities for the pharmaceutical sector for the development of novel multispecific antibodies. Despite their encouraging response in the management of several diseases, the high costs involved in the development of multispecific antibodies with advanced techniques act as a major restrain for the market due to the complex production process, expensive biological and chemical materials, and clinical trials, as well as required safety, efficacy, and quality tests.
The global pipeline for novel multispecific antibodies is highly crowded and is indicated for the management of wide range of therapeutic conditions including cancer, autoimmune disorder, HIV, and other chronic disorders. As per our analysis, the global multispecific antibody market will surpass US$ XX Billion by 2028. There are many factors, such as increase in incidence of cancer, rise in healthcare expenditure, increased access to medical insurance, and technological advancements in cancer treatment therapies that fuel the growth of the global bispecific antibodies market. In addition, rising initiatives by government and subsequent development of favorable reimbursement policies also acts as driver to the market.
The report provides information on the currently available multispecific antibodies in the market with their dosage, patent, price, and sales forecast till 2028. In addition, the report also provides insights into ongoing clinical trials in the market and the major drugs present in research and development. Further, global and regional market analysis has also been done. In addition, various multispecific antibody development platforms by companies are also included in the report.
For More Information Related To Report Contact:
Neeraj Chawla
Research Head
Kuick Research
+919810410366